Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptamer GroupLSE:APTA 3-Year EBITDA Growth Rate is 68.80% as of Dec. 2025, which is 391% above its 10-year median of 14.00. The stock has 4 warning signs investors should review. Among 1,127 Biotechnology companies, Aptamer Group ranks better than 93.08% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 68.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aptamer Group was 68.80% per year. The lowest was -125.70% per year. And the median was 14.00% per year.
Aptamer Group (LSE:APTA) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aptamer Group 3-Year EBITDA Growth Rate Related Terms
LSE:APTA vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Aptamer Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptamer Group 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptamer Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aptamer Group's 3-Year EBITDA Growth Rate falls into.
Aptamer Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 68.80% mean?
Aptamer Group (LSE:APTA) has a 3-Year EBITDA Growth Rate of 68.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aptamer Group and its competitors. This is 391% above median its historical median of 14.00. According to the industry distribution chart, Aptamer Group ranks #78 out of 1127 companies in the Biotechnology industry, placing it in the top 6.9%.
Is Aptamer Group's 3-Year EBITDA Growth Rate too high?
Aptamer Group's current 3-Year EBITDA Growth Rate of 68.80% is 391% above median its 10-year median of 14.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Aptamer Group's value of 68.80% is 368% above this industry median. Based on the distribution chart, Aptamer Group ranks #78 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Aptamer Group's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptamer Group ranks #78 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Aptamer Group in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Aptamer Group's value of 68.80% is 368% above this benchmark. While the company's 10-year median is 14.00 vs. the industry median of 14.70, Aptamer Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptamer Group's current 3-Year EBITDA Growth Rate of 68.80% is 368% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aptamer Group and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptamer Group's current 3-Year EBITDA Growth Rate is 68.80%, which is 391% above median its own 10-year median of 14.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptamer Group stock overvalued right now?
Aptamer Group (LSE:APTA) has a current 3-Year EBITDA Growth Rate of 68.80%. The current 3-Year EBITDA Growth Rate is 68.80%, which is 391% above median its 10-year median of 14.00 and 368% above the Biotechnology industry median of 14.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aptamer Group (LSE:APTA), the current 3-Year EBITDA Growth Rate is 68.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses, Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics. The Group represents a single operating segment being research and experimental development of biotechnology. It operates in United Kingdom, Europe, USA and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:APTA has been successfully added to your 
